Anzeige

Archive

Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: https://doi.org/10.1160/TH10-10-0631
Issue: 2011: 105/6 (June) pp. 933–1123
Pages: 1072-1079

Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery

J. Windyga (1), M. von Depka-Prondzinski (2), on behalf of the European Wilate® Study Group

(1) Institute of Haematology and Transfusion Medicine, Warsaw, Poland; (2) Werlhof Institute, Hannover, Germany

Keywords

surgery, von Willebrand factor, factor VIII, von Willebrand disease, Wilate®

Summary

The aim of this study was to assess the efficacy of Wilate®, a new generation, plasma-derived, high-purity, double virus-inactivated von Willebrand factor (VWF) and factor VIII (FVIII) concentrate (ratio close to physiological 1:1) in the perioperative management of haemostasis in von Willebrand disease (VWD). Data for VWD patients who received Wilate® for perioperative management were obtained from four European, prospective, open-label, non-controlled, non-randomised, multicentre phase II or III clinical trials. A total of 57 surgical procedures were performed (major: n = 27; minor n = 30) in 32 patients. The majority of patients (n = 19, 59.4%) had type 3 VWD, 9 (28.1%) had type 2 VWD and four (12.5%) had type 1 VWD. During major surgery, median daily FVIII dose and mean number of infusions were 25 IU•kg-1 FVIII (VWF:RCo ~23 IU•kg-1) and 11.0, respectively. Corresponding values for minor surgery were 35 IU•kg-1 (VWF:RCo ~32 IU•kg-1) and 1.5. The efficacy of Wilate® was rated by the investigator as excellent or good in 51 of 53 (96%) procedures. Tolerability was rated as very good or good in 100% of major surgeries (27 of 27) and minor surgeries (29 of 29). Wilate® is an effective and well-tolerated VWF/FVIII replacement therapy in the perioperative management of haemostasis in patients with VWD. It can be administered at a similar FVIII dose, but at a lower VWF dose, as compared to older generation products. Clinical benefits were shown in a population with a high proportion of type 3 VWD patients.

You may also be interested in...

1.

Steven W. Pipe

Thromb Haemost 2008 99 5: 840-850

https://doi.org/10.1160/TH07-10-0593

2.
Carolyn M. Millar 1, Anne F. Riddell 1, Simon A. Brown 1, Richard Starke 2, Ian Mackie 2, Derrick J. Bowen 3, P. Vincent Jenkins 1, Jan A. van Mourik4

Thromb Haemost 2008 99 5: 916-924

https://doi.org/10.1160/TH07-09-0565

3.
Alessandra Casonato, Francesca Sartorello, Elena Pontara, Lisa Gallinaro, Antonella Bertomoro, Maria Grazia Cattini, Viviana Daidone, Maryta Szukowska, Antonio Pagnan

Thromb Haemost 2007 98 6: 1182-1187

https://doi.org/10.1160/TH07-05-0347